Stockscreener 앱 받기
0.7217
0.44%
-0.0032
시간 외 거래:
29.72
29.00
+4,018%
전일 마감가:
$0.7249
열려 있는:
$0.716
하루 거래량:
614.34K
Relative Volume:
0.37
시가총액:
$23.95M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-0.2207
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
+17.35%
1개월 성능:
+154.03%
6개월 성능:
-76.10%
1년 성능:
-75.37%
1일 변동 폭
$0.68
$0.7497
1주일 범위
$0.5804
$0.7497
52주 변동 폭
$0.2404
$4.47
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.34 | 372.90M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
10.80 | 210.86M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.98 | 128.54M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.16 | 350.11M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.34 | 398.00M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada Therapeutics Holds Annual Stockholders Meeting - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Lowered to Strong Sell Rating by Wall Street Zen - Defense World
RELMADA THERAPEUTICS Executives Make Significant Stock Purchases in May 2025 - TradingView
Relmada Therapeutics Executives Make Bold Stock Purchases! - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Relmada Therapeutics’ Earnings Call: Promising Data Amid Financial Concerns - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Relmada Therapeutics’ Q1 2025 results miss EPS expectations - Investing.com
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... - Yahoo Finance
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights - GuruFocus
Relmada Therapeutics Reports Q1 2025 Financial Results - TipRanks
Transcript : Relmada Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Relmada Therapeutics to Report First Quarter 2025 Financial Resu - GuruFocus
Relmada Therapeutics (RLMD) Expected to Announce Earnings on Monday - Defense World
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - The Manila Times
Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress - Nasdaq
Renaissance Technologies LLC Buys 138,625 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World
Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com
It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX
Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - EIN News
Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com
Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada
Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com
SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow
Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider
Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan
Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus
Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus
Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times
Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News
RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Relmada Therapeutics Inc (RLMD) receives a Neutral rating from Mizuho - knoxdaily.com
RLMD Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 0.8% – Should You Sell? - Defense World
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
자본화:
|
볼륨(24시간):